Bright Minds Biosciences Inc DRUG

$48.25 -1.54 (-3.09%)

Valuation

Market cap
484,566,000
Revenue TTM
$0
Net income TTM
$-8,740,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
107,600
Avg volume
127,084
Day's range
$47.60 – $50.00
Shares out
9,732,000
Stochastic %K
6%
Beta
-5.22
Analysts
Strong Sell
Price target
$154.83

Price

Company profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmenta...

Show more

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
647 865 8622
Website
https://brightmindsbio.com
Address
19 Vestry Street, New York, United States

Latest news

Stocktwits

VegasG Oct 5, 1:49 PM
$DRUG ALMIGHTY 80 bagger millionairs made
0 replies
dcpanda Oct 4, 10:10 AM
$ICU get ready, low float supply and demand hyperbolic move can be coming. Remember $DRUG
2 replies
Anonymous123 Oct 2, 3:47 PM
$IBRX whats the price if FDA approves it? Will it be a another $DRUG
1 replies
focafoca99 Sep 30, 9:50 PM
$DRUG rescinded 44,500 common stock options in a mutual release, returning the shares to treasury and refunding the exercise price.
0 replies
Dark_Prince Sep 30, 12:57 AM
I miss trading with my buddies. We used to trade together and had one of the best fun times. Now its all just me. I am dark prince baby 😎 $SGRP $PTIX $BGI $DRMA $DRUG
4 replies
416trader Sep 24, 8:40 PM
$TRAW Perceptive Advisors lead by Joseph Edelman does not fail. Biggest winner was $DRUG
0 replies
CoffeeRocks Sep 21, 12:36 PM
$DRUG $HOLO $INHD $RETO $RGC
0 replies
DaSqueeza Sep 18, 9:35 PM
$AEMD is giving me some serious $DRUG vibes. Both are small-cap biotech stories driven by potentially high-value drug/clinical assets — different therapeutic areas, but a similar setup where the market can suddenly reprice the underlying biotech opportunity. Now add the trading mechanics: 🔥 Share price climbing 🔥 CTB ~511% and rising 🔥 IBKR borrow: 450K+ → ZERO 🔥 Price still holding the $6–7 area That combination of biotech repricing + tightening liquidity is what makes the $DRUG analogy interesting. Not saying $AEMD will repeat the $DRUG move — but rising price + rising CTB + zero borrow is exactly the kind of recipe worth watching. Now it needs VOLUME. 👀
0 replies